CRESCENT BIOPHARMA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CRESCENT BIOPHARMA, INC. (CBIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.96M, a 2.53% decline year-over-year.
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.69M, a 691.85% increase year-over-year.
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.99M, a 75.20% increase year-over-year.
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.07M, a 236.94% increase year-over-year.
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.00M, a 91.65% increase from fiscal 2024.
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $4.70M, a 33.28% increase from fiscal 2023.
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.52M, a 8.64% decline from fiscal 2022.
- CRESCENT BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.86M, a 36.63% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 0 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.96M 10-Q · filed 2026-07-30 | $7.66M derived: sum of 2 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $3.69M 10-Q · filed 2026-07-30 | |||||
| 2025-12-31 | $9.00M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $1.99M 10-Q · filed 2025-11-06 | $6.06M derived: sum of 2 quarters · filed 2026-07-30 | $6.53M derived: sum of 3 quarters · filed 2026-07-30 | $7.60M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $4.07M 10-Q · filed 2026-07-30 | $4.53M derived: sum of 2 quarters · filed 2026-07-30 | $5.61M derived: sum of 3 quarters · filed 2026-07-30 | $6.75M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $466.00K 10-Q · filed 2026-07-30 | $405.43K 10-Q · filed 2025-05-14 | $1.54M derived: sum of 2 quarters · filed 2026-07-30 | $2.68M derived: sum of 3 quarters · filed 2026-07-30 | $3.88M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2024-12-31 | $1.07M 10-K · filed 2026-02-26 | $2.21M derived: sum of 2 quarters · filed 2026-02-26 | $3.42M derived: sum of 3 quarters · filed 2026-02-26 | $4.70M 10-K · filed 2025-02-13 | ||
| 2024-09-30 | $69.00K 10-Q · filed 2025-11-06 | $1.14M 10-Q · filed 2024-11-13 | $2.35M derived: sum of 2 quarters · filed 2024-11-13 | $3.54M derived: sum of 3 quarters · filed 2025-05-14 | ||
| 2024-06-30 | $1.21M 10-Q · filed 2024-11-13 | $2.40M derived: sum of 2 quarters · filed 2025-05-14 | ||||
| 2024-03-31 | $1.19M 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | $3.52M 10-K · filed 2025-02-13 | |||||
| 2023-09-30 | $887.84K 10-Q · filed 2024-11-13 | $1.75M derived: sum of 2 quarters · filed 2024-11-13 | $2.62M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $858.09K 10-Q · filed 2024-11-13 | $1.73M derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $870.18K 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | $3.86M 10-K · filed 2024-03-27 | |||||
| 2022-09-30 | $913.98K 10-Q · filed 2023-11-03 | $1.88M derived: sum of 2 quarters · filed 2023-11-03 | $2.96M derived: sum of 3 quarters · filed 2023-11-03 | |||
| 2022-06-30 | $963.76K 10-Q · filed 2023-11-03 | $2.04M derived: sum of 2 quarters · filed 2023-11-03 | ||||
| 2022-03-31 | $1.08M 10-Q · filed 2023-11-03 | |||||
| 2021-12-31 | $6.09M 10-K · filed 2024-03-27 | |||||
| 2021-09-30 | $1.59M 10-Q · filed 2022-11-09 | $3.15M derived: sum of 2 quarters · filed 2022-11-09 | $4.77M derived: sum of 3 quarters · filed 2022-11-09 | $6.39M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2021-06-30 | $1.56M 10-Q · filed 2022-11-09 | $3.18M derived: sum of 2 quarters · filed 2022-11-09 | $4.80M derived: sum of 3 quarters · filed 2023-03-29 | $6.49M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2021-03-31 | $1.61M 10-Q · filed 2022-11-09 | $3.24M derived: sum of 2 quarters · filed 2023-03-29 | $4.93M derived: sum of 3 quarters · filed 2023-03-29 | $6.69M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2020-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $3.32M derived: sum of 2 quarters · filed 2023-03-29 | $5.08M derived: sum of 3 quarters · filed 2023-03-29 | $6.90M 10-K · filed 2023-03-29 | ||
| 2020-09-30 | $1.69M 10-Q · filed 2021-11-02 | $3.45M derived: sum of 2 quarters · filed 2021-11-02 | $5.27M 10-Q · filed 2020-11-06 | $7.00M derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2020-06-30 | $1.76M 10-Q · filed 2021-11-02 | $1.76M 10-Q · filed 2020-07-31 | $3.58M 10-Q · filed 2020-07-31 | $5.31M derived: sum of 3 quarters · filed 2022-03-03 | $6.90M derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-03-31 | $1.82M 10-Q · filed 2021-11-02 | $3.55M derived: sum of 2 quarters · filed 2022-03-03 | $5.14M derived: sum of 3 quarters · filed 2022-03-03 | $6.65M derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2019-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $3.31M derived: sum of 2 quarters · filed 2022-03-03 | $4.83M derived: sum of 3 quarters · filed 2022-03-03 | $6.22M 10-K · filed 2022-03-03 | ||
| 2019-09-30 | $1.59M 10-Q · filed 2020-11-06 | $3.11M derived: sum of 2 quarters · filed 2020-11-06 | $4.49M 10-Q · filed 2020-11-06 | $5.64M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-06-30 | $1.52M 10-Q · filed 2020-07-31 | $2.90M 10-Q · filed 2020-07-31 | $4.05M derived: sum of 3 quarters · filed 2021-03-02 | $5.22M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-03-31 | $1.38M 10-Q · filed 2020-05-01 | $2.53M derived: sum of 2 quarters · filed 2021-03-02 | $3.70M derived: sum of 3 quarters · filed 2021-03-02 | $4.85M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2018-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $2.32M derived: sum of 2 quarters · filed 2021-03-02 | $3.47M derived: sum of 3 quarters · filed 2021-03-02 | $4.59M 10-K · filed 2021-03-02 | ||
| 2018-09-30 | $1.17M 10-Q · filed 2019-11-07 | $2.32M derived: sum of 2 quarters · filed 2019-11-07 | $3.44M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $1.15M 10-Q · filed 2019-08-01 | $2.27M 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | $1.12M 10-Q · filed 2019-05-02 | |||||
| 2017-12-31 | $3.76M 10-K · filed 2020-02-28 | |||||
| 2016-12-31 | $2.96M 10-K · filed 2019-03-06 | |||||
| 2015-12-31 | $2.32M 10-K · filed 2018-03-06 | |||||
| 2014-12-31 | $1.64M 10-K · filed 2017-03-01 | |||||
| 2013-12-31 | $425.69K 10-K · filed 2016-02-29 | |||||
| 2012-12-31 | $415.21K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |